Plain-English translation of NCT06249048 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This is a first-in-human study testing , a new treatment injected directly into cancer tumors in patients with advanced solid cancers. The study is examining whether this medication is safe and how well it works, either used alone or combined with pembrolizumab, an immunotherapy drug that helps your immune system fight cancer. Researchers will carefully watch for side effects and measure how tumors respond to treatment.
Many advanced cancers stop responding to standard treatments or immunotherapy alone. This medication represents a new approach by delivering treatment directly into tumors, which may help the immune system recognize and attack cancer cells more effectively.
You likely qualify if…
You likely don't qualify if…
You would visit the study center multiple times to receive injections of the medication directly into your tumor. Depending on which phase of the study you enter, you may receive the medication alone or in combination with pembrolizumab infusions. Throughout the study, you'll have blood tests, imaging scans, and possibly tumor biopsies to monitor how you're responding. The treatment phase can last up to approximately 24 months, with regular follow-up visits to check your health and track any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States